Zonisamide: A new antiepiletic drug

Polish Journal of Pharmacology

Volumn 55, Issue 5, 2003, Pages 683-689

  Sobieszek, Grzegorz ^a   Borowicz, Kinga Kornel ^a   Kimber Trojnar, Zaneta ^a   Małek, Robert ^a   Piskorska, Barbara ^a   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Clinical trials; Epilepsy; Experimental seizures; Zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM CHANNEL T TYPE; CARBAMAZEPINE; FREE RADICAL; MONOAMINE; PHENYTOIN; VALPROIC ACID; VOLTAGE GATED POTASSIUM CHANNEL; ZONISAMIDE; ISOXAZOLE DERIVATIVE;

ANOREXIA; ATAXIA; CLINICAL TRIAL; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EPILEPSY; FATIGUE; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; IRRITABILITY; MANIA; MIGRAINE; MONOTHERAPY; MOUSE; NAUSEA; NEPHROLITHIASIS; NEUROPATHIC PAIN; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; OLIGOHYDROSIS; PARKINSON DISEASE; RESTLESSNESS; REVIEW; SIDE EFFECT; SOMNOLENCE; TERATOGENESIS; VERTIGO; ANIMAL;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS; EPILEPSY; HUMANS; ISOXAZOLES;

EID: 0346327429     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca E.: Progress report on new antiepileptic drugs: a summary of the Fourth Eilat Conference (EILAT IV). Epilepsy Res., 1999, 34, 1-41.
2. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca E.: Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res., 2001, 43, 11-58.
3. Bialer M., Johannessen S.I., Kupferberg H.J., Levy R.H., Loiseau P., Perucca E.: Progress report on new antiepileptic drugs: a summary of the Six Eilat Conference (EILAT VI). Epilepsy Res., 2002, 51, 31-71.
4. Brodie M.J.: Drug interactions and epilepsy. Epilepsia, 1992, 33, 13-22.
5. Browne T.R., Holmes G.L.: Epilepsy. New Engl. J. Med., 2001, 344, 1145-1151.
6. Cornford E.M., Landon K.P.: Blood brain barrier transport of CI-912: single-passage equilibration of erythrocyte-borne drug. Ther. Drug Monit., 1985, 7, 247-254.
7. Hamada K., Song H.K., Ishida S., Yagi K., Seino M.: Contrasting effects of zonisamide and acetazolamide on amygdaloid kindling in rats. Epilepsia, 2001, 42, 1379-1396.
8. Hashiguchi W., Nagatomo I., Akasaki Y., Uchida M., Tominaga M., Takigawa M.: Influence of caffeine on nitric oxide production and zonisamide concentration in the brain of seizure-susceptible EL mice. Psychiat. Clin. Neurosci., 2001, 555, 319-324.
9. Hashimoto Y., Araki H., Futagami K., Kawasaki H., Gomita Y.: Effects of valproate, phenytoin, and zonisamide on clonic and tonic seizures induced by acute and repeated exposure of mice to flurothyl. Physiol. Behav., 2003, 78, 465-469.
10. Hashimoto Y., Suemaru K., Yamamoto T., Kawakami K., Araki H., Gomita Y: Effect of immobilization stress on anticonvulsant actions and pharmacokinetics of zonisamide in mice. Pharmacol. Biochem. Behav., 2001, 68, 7-12.
11. Hayakawa T., Higuchi H., Nigami H., Hattori H.: Zonisamide reduces hypoxic-ischemic brain damage in neonatal rats irrespective of its anticonvulsive effect. Eur. J. Pharmacol., 1994, 257, 131-135.
12. Henry T.R., Leppik I., Gumnit R.J., Jacobs M.: Progressive myoclonic epilepsy treated with zonisamide. Neurology, 1988, 38, 928-931.
13. Hori M., Ito T., Oka M., Noda Y., Matsuno Y., Furukawa K., Ochi Y, Karasawa T., Kadokawa T.: General pharmacology of novel antiepileptic compound zonisamide. 1st communication: effects on central nervous system. Arzneim.-Forsch.-Drug Res., 1987, 37, 1124-1130.
14. Kamei C., Oka M., Masuda Y., Yoshida K., Shimizu M.: Effects of 3-sulfamylomethyl-1,2-benzisoxazole (AD-810) and some antiepileptics on the kindled seizures in the neocortex, hippocampus and amygdala in rats. Arch. Int. Pharmacodyn. Thér., 1981, 249, 164-176.
15. Kanba S., Yagi G., Komijima K., Suzuki T., Tajima O., Otaki J., Arata E., Koshikawa H., Nibuya M., Kinoshita N.: The first open study of zonisamide: a novel anticonvulsant shows efficacy in mania. Prog. Neuro-Psych. Biol. Psych., 1994, 18, 705-715.
16. Kimura M., Tanaka N., Kimura Y, Miyake K., Kitara T., Fukuchi H.: Zonisamide and its properties. J. Pharmacobiodyn., 1992, 15, 631-639.
17. Kondo T., Kaneko S., Amano Y., Egawa I.: Preliminary report on teratogenic effects in the offspring of treated women with epilepsy. Epilepsia, 1996, 37, 1242-1244.
18. Löscher W.: Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res., 2002, 50, 105-123.
19. Löscher W.: Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol. Sci., 2002, 23, 113-118.
20. Masuda Y., Ishaizaki M., Shimizu M.: Zonisamide: pharmacology and clinical efficacy in epilepsy. CNS Drug Rev., 1998, 4, 341-360.
21. Masuda Y., Karasawa T., Shiraishi Y, Han M., Yosida K., Shimizu M.: 3-Sulfamylomethyl-1,2-benz-isoxazole, a new type of anticonvulsant drug. Pharmacological profile. Arzneim.-Forsch. -Drug Res., 1980, 30, 477-483.
22. Masuda Y., Utsui Y., Shiraishi Y., Karasawa T., Yoshida K., Shimizu M.: Relationships between plasma concentrations of diphenylhydantoin, phenobarbital, carbamazepine, and 3-sulfamylomethyl-1,2-benz-isoxazole (AD810), a new anticonvulsant agent, and their anticonvulsant or neurotoxic effects in experimental animals. Epilepsia, 1979, 20, 623-633.
23. McCumber D., Chen K.S., Meyer K.B., Yaksh T.L.: A study of zonisamide (Zonegran) in the formalin model of nociception. J. Pain, 2002, 3, Suppl. 1, 29.
24. McJilton J., DeToledo J., Decerce J.: Cotherapy of lamotrigine/zonisamide results in significant elevation of zonisamide levels. Epilepsia, 1996, 37, Suppl. 5, 173.
25. Mimaki T., Mino M.: Neuropharmacological aspects of specific [3H] zonisamide bindig site in rat brain. Ann. Rep. Jpn. Epil. Res. Found., 1990, 2, 19-29.
26. Mimaki T., Suzuki Y., Tagawa T, Tanaka J., Itoh N., Yabuuchi H.: [3H] Zonisamide binding in rat brain. Jpn. J. Psychiat. Neurol., 1989, 42, 640-642.
27. Minato H., Kikuta C., Fuijtani B., Masuda Y.: Protective effect of zonisamide, an antiepileptic drug against transient focal cerebral ischemia with middle cerebral artery occlusion-preperfusion in rats. Epilepsia, 1997, 38, 975-980.
28. Mori A., Noda Y., Packer L.: The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res., 1998, 30, 153-158.
29. Murata M., Horiuchi E., Kanazawa I.: Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci. Res., 2001, 41, 397-399.
30. Nagamoto I., Akasaki Y., Uchida M., Tominaga M., Hashiguchi W., Takigawa M.: Effects of combined administration of zonisamide and valproic acid or phenytoin to nitric oxide production, monoamines and zonisamide concentrations in the brain of seizure-susceptible EL mice. Brain Res. Bull., 2000, 53, 211-218.
31. Nagatomo I., Akasaki Y., Nagase F., Nomaguchi M., Takigawa M.: Relationships between convulsive seizures and serum and brain concentrations of phenobarbital and zonisamide in mutant inbred strain EL mouse. Brain Res., 1996, 731, 190-198.
32. Nakatsuji K., Matsuno Y., Nakamura N., Fujitani B., Ito T., Kadokawa T.: General pharmacology of novel antiepileptic compound zonisamide. 2nd communication: effects on cardiovascular, visceral, renal, and blood functions. Arzneim.-Forsch.-Drug Res., 1987, 37, 1131-1136.
33. Nishiguchi K., Ohnishi N., Iwakawa S., Yagi Y., Nakayama S., Takada S., Nakamura H., Yokoyama T., Okumura K.: Pharmacokinetics of zonisamide: saturable distribution into human and rat erythrocytes and into rat brain. J. Pharmacobiodyn., 1992, 15, 409-415.
34. Ojemann L.M., Shastri R.A., Wilensky A.J., Friel P.N., Levy R.H., McLean JR., Bauchanan R.A.: Comparative pharmacokinetic of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther. Drug Monit., 1986, 8, 293-296.
35. Okada M., Hirano T., Kawata Y., Murakami T., Wada K., Mizuno K., Kondo T., Kaneko S.: Biphasic effects of zonisamide on serotoninergic system in rat hippocampus. Epilepsy Res., 1999, 34, 187-197.
36. Okada M., Kaneko S., Hirano T., Mizuno K., Kondo T., Otani K., Fukushima Y.: Effects of zonisamide on dopaminergic system. Epilepsy Res., 1995, 22, 193-205.
37. Oomen K.J., Mathews S.: Zonisamide, a new antiepileptic drug. Clin. Neuropharmacol., 1999, 22, 192-200.
38. Owen A.J., Ijaz S., Miyashita H., Wishart T., Howlett W., Shuaib A.: Zonisamide as neuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vivo microdialysis and behavioral study. Brain Res., 1997, 770, 115-122.
39. Penry J.K., Newmark M.E.: The use of antiepileptic drugs. Ann. Int. Med., 1979, 90, 207-218.
40. Peters D.H., Sorkin E.M.: Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs, 1993, 45, 760-787.
41. Rock D.M., Macdonald R.L., Taylor C.P.: Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD810, C 1912), a novel anticonvulsant. Epilepsy Res., 1989, 3, 138-143.
42. Sackellares J.C., Donofrio P.D., Wagner J.G., AbouKhalil B., Berent S., Aasved-Hoyt K.: Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia, 1985, 26, 206-211.
43. Seino M., Ito T.: Zonisamide. In: Epilepsy: a Comprehensive Textbook. Eds. Enge L.J., Pedley T.A., Lipinocott-Raven, Philadelphia, 1997, 1619-1626.
44. Seino M., Miyzaki H., Ito T.: Zonisamide. In: New Antiepileptic Drugs (Epilepsy Res., Suppl. 3). Eds. Pisani F., Perucca E., Avanzini G., Richens A., Elsevier Science, Amsterdam, 1991, 169-174.
45. Shellenberger K., Shah J., Dunkley L., Floren L.: Multiple-dose pharmacokinetics of antiepileptic drugs in the presence of zonisamide. Zonegran Scientific Exhibit at the American Epilepsy Society Annual Meeting. 4 December 2001, Philadelphia, 4-5.
46. Shinnar S., Berg A.T.: Does antiepileptic drug therapy prevent the development of chronic epilepsy. Epilepsia, 1996, 37, 701-708.
47. Suzuki S., Kawakami K., Nishimura S., Watanabe Y., Yagi K., Seino M., Miyamoto K.: Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res., 1992, 12, 21-27.
48. Suzuki Y., Magai T., Ono J., Imai K., Ostani K., Tagawa T., Abe J., Shiomi M., Okada S.: Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia, 1997, 38, 1035-1038.
49. Tomlinson D.R., Malcongio M., Patel J., Meyer K.B., Chen S.: Effects of zonisamide on mechanically induced nociception in rats with streptozotocin-diabetes. In: Worldwide Pain Conference Proceedings, Program and Abstract of the Worldwide Pain Conference, 15-21 July 2000, San Francisco CA, 160.
50. Trojnar M.K., Małek R., Chrościńska M., Nowak S., Błaszczyk B., Czuczwar S.J.: Neuroprotective effects of antiepileptic drugs. Pol. J. Pharmacol., 2002, 54, 557-566.
51. Uno H., Kurokawa M., Masuda Y., Nishimura H.: Studies on 3-substituted 1,2-benzisoxazole derivates. Syntheses of 3-(sulfamoylmethyl)-1,2-benzisoxazole derivatives and their anticonvulsant activities. J. Med. Chem., 1979, 22, 180-183.
52. Wada Y., Hasegawa H., Okuda H., Yamaguchi N.: Anticonvulsant effect of zonisamide and phenytoin on seizure activity of the feline visual cortex. Brain Dev., 1990, 12, 206-210.